Middle East & Africa Cervical Cancer Diagnostics and Therapeutics Market Research Report - Segmented By Diagnostics Test, Methods, Therapies, End-users & By Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 776
Pages: 130

MEA Cervical Cancer Diagnostics and Therapeutics Market Size (2024 to 2029)

The Middle East & Africa Cervical Cancer Diagnostics and Therapeutics market is predicted to be worth USD 377.52 million by 2029  from USD 306.59 million in 2024, growing at a CAGR of 4.25% during the forecast period.  

The growing adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to boost the MEA cervical cancer diagnostics and therapeutics market. The increased awareness of cervical cancer in women and the focus by cancer organizations around the world and governments on early testing to detect and prevent cervical cancer contribute to market growth in the region.

According to the Saudi National Cancer Registry report, the Kingdom of Saudi Arabia has 19.6 million (15.6 million Saudis and 4.9 million expatriates), of which 52% are Saudi women. There are 3.56 million Saudi women between the ages of 15 and 65. Cervical cancer is the ninth most common malignant tumor in Saudi women, accounting for 1.69% of newly diagnosed cancer cases. The health services in the Kingdom of Saudi Arabia thus have launched many nationwide public education and screening programs for awareness. This data shows the upcoming market growth in the Middle East region for the upcoming period.

Increased awareness among the general population about the care, prevention, and treatment of cervical cancer, increased behaviors such as sex with multiple partners and smoking, certain genetic factors, and a weakened immune system are linked to the growth of the cervical cancer diagnostic and therapeutics market in the MEA region.

However, high capital investments and rising prices of imaging systems affecting their acceptance rate in developing markets are the key factors that may restrain the MEA market during the forecast period. The pandemic has significantly affected the availability of hospital resources around the world. This was initially managed by drastically reducing inpatient and outpatient services for other illnesses and implementing infection prevention and control measures. As a result, the number of diagnosing and detecting cancer methods has been drastically reduced, and the pandemic is affecting the MEA market growth rate.

This research report on the MEA Cervical Cancer Diagnostics and Therapeutics Market is segmented and sub-segmented into the following categories:

By Diagnostics Test:

  • Pap Smear Test
  • HPV Testing
  • Colposcopy
  • Cervical Cancer Biopsy

By Methods:

  • Molecular Method
  • Cytopathological Method
  • Physical Method

By Therapies:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Others

By End-users:

  • Hospitals
  • Laboratories
  • Independent Physicians
  • Clinics
  • Others

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, The Middle East has the largest market in 2020 in the MEA region and is expected to remain the largest market during the forecast period. The regional market's growth can be attributed to high health expenditure per capita and favorable health policies.

The United Arab Emirates is expected to be the fastest-growing region and is expected to remain the fastest-growing region during the forecast period. Factors behind the faster growth of the UAE region include a largely untapped market base, which has shown technological development in health research over the past decade. In addition, significantly higher investments in health research and economic improvement are expected from these regions to boost the market potential during the forecast period.

The African region is expected to show small growth in the near future due to a lack of an established healthcare system, the availability of skilled technicians at a comparatively lower cost, and a defined regulatory framework that favors expedited products approvals. In addition, the booming medical tourism industry in countries like Qatar, Turkey, and Saudi Arabia is expected to drive demand for cancer screening and therapeutics.


A few of the leading companies operating in the MEA Cervical Cancer Diagnostics and Therapeutics market profiled in this report are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, EDP Biotech, Epigenomics AG, Exact Sciences, Fujirebio, Genomic Tree, Metabiomics, Oncocyte (Biotime), Quest Diagnostics, Randox Laboratories, Siemens Healthcare, and Volition Rx.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample